Key Dates

Related Announcements

PA-20-187 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed)

PA-20-189 - NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

PA-20-201 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)

PA-20-202 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)

PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

PAR-21-111 - The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)

PAR-21-128 - The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)

PAR-21-295 - NCI Mentored Research Scientist Development Award to Promote Diversity (K01 – Independent Clinical Trial Not Allowed)

PAR-21-296 - NCI Mentored Research Scientist Development Award to Promote Diversity (K01 - Clinical Trial Required)

PAR-21-299 - NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)

PAR-21-300 - NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed)

PAR-21-301 - NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)

PAR-21-302 - The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)

PAR-21-318 - NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Required)

Issued by

National Cancer Institute (NCI)

Purpose

This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.

Background

The Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) supports research that adances the application of the mechanistic and scientific understanding of carcinogenesis and human biology towards interventions focused on cancer prevention, interception, screening and early detection, and symptom management. These mechanistic understandings can come from research conducted across basic science, epidemiology, behavioral, or clinical studies and by varied scientific disciplines. DCP also supports research spanning the full translational spectrum, from preclinical (e.g., cell and tissue culture, animal models) to clinical (e.g., small early phase clinical trials to large phase three studies) research. Key to advancing the work of DCP and developing successful interventions is having a robust workforce trained in translational cancer prevention research, including cancer interception, screening and early detection, and symptom science strategies and methods.

To this end, the NCI Cancer Training Branch in the Center for Cancer Training, Diversity Training Branch in the Center to Reduce Cancer Health Disparities, and DCP are issuing this announcement to stimulate applications from early-career scientists conducting research within the mission of DCP to existing career development funding opportunities.

Research Objectives

Priority research areas for DCP include but are not limited to:

• Cancer Prevention/ Interception
  • Identifying novel targets for cancer prevention and interception, including targetable pathways, neoantigens, and tumor-associated antigens present early in cancer development;
  • Developing novel cancer preventive interventions, including natural products, dietary factors, small molecules, and cancer preventive vaccines or procedures;
  • Developing precision prevention strategies for average- and high-risk populations, the latter including people with germline mutations that increase cancer risk, individuals with obesity, cancer survivors, and people living with HIV;
  • Conducting interventional trials focused on prevention/interception of cancer using novel or updated agents, methods or approaches, screening tests, or agent delivery strategies; and
  • Developing and validating novel cancer preventive agent delivery strategies, such as sustained release and topical drug delivery, to reduce the harms related to systemic exposure.
• Cancer Early Detection/ Screening
  • Discovery, development, evaluation, and validation of molecular and imaging biomarkers and their applications for early cancer detection (the discrimination between benign, precancerous and early malignant lesions) and risk assessment;
  • Liquid biopsy studies on detection and/or quantification of circulating DNA, miRNA, exosomes, extracellular vesicles (EVs), etc., from blood and other bodily fluids with specific focus on pre- cancer and early cancer detection and/or risk assessment for cancer development;
  • Identifying and validating biomarkers and screening methods for all cancers, including cancers that are currently the most lethal and recalcitrant;
  • Developing and validating novel screening tools and strategies, such as self-sampling, self-testing, and point-of-care testing to increase accessibility and acceptability of cancer screening for all populations;
  • Conducting retrospective analyses of existing biospecimens, such as biospecimens collected from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the National Lung Cancer Screening Trial (NLST), and others, collected within clinical trials or cohort studies to evaluate molecular imaging or epidemiological biomarkers for early detection and risk stratification.
• Symptom Science
  • Understanding the biology of cancer therapy symptoms to inform precision symptom management;
  • Understanding the role of the host susceptibility or risk factors as predictors of cancer treatment-related side effects;
  • Identifying and validating novel agents, including natural products, dietary factors, medicines, and drugs, for symptom prevention, treatment and control;
  • Discovering and developing agents aimed at preventing and treating acute, late, and chronic cancer treatment-related symptoms and toxicities including but not limited to cardiotoxicity, fatigue, neuropathy, lymphedema, cognitive decline, pain, or cachexia.

Application and Submission Information

This notice applies to due dates on or after February 12, 2023, and subsequent receipt dates through November 13, 2024.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice.

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-CA-23-035” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• All applicants are strongly encouraged to contact the NCI program contacts, listed below, to discuss the specific aims of the application before submission.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Scientific/Research Contact(s)

(For questions related to the Division of Cancer Prevention research interests)

Jessica Faupel-Badger
National Cancer Institute (NCI)
Telephone: 240-276-7296
Email: [email protected]

(For applications related to training and early investigator development within the Cancer Training Branch/Center for Cancer Training)

Nastaran Zahir
National Cancer Institute (NCI)
Telephone: 240-276-6333
Email: [email protected]

(For applications related to training and early investigator development within the Diversity Training Branch/Center to Reduce Cancer Health Disparities)

Behrous Davani
National Cancer Institute (NCI)
Telephone: 240-276-6170
Email: [email protected]